Suvorexant
- Generic Name
- Suvorexant
- Brand Names
- Belsomra
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN6O2
- CAS Number
- 1030377-33-3
- Unique Ingredient Identifier
- 081L192FO9
- Background
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
- Indication
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
Phase 3
Completed
- Conditions
- Primary Insomnia
- Interventions
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1023
- Registration Number
- NCT01097616
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01059851
Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01043926
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
Phase 3
Completed
- Conditions
- Insomnia
- Interventions
- Drug: Dose-matched Placebo to Suvorexant
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 781
- Registration Number
- NCT01021813
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
Phase 2
Completed
- Conditions
- Primary Insomnia
- Interventions
- Drug: Dose-matched Placebo to Suvorexant
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 254
- Registration Number
- NCT00792298
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath